Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutationFilip Jankú, Alex A. Adjei, Debora Schmitz et al.|Molecular Cancer Therapeutics|2019Cited by 7